Trial watch: Chemotherapy with immunogenic cell death inducers

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Vacchelli, Erika ^a,b,c   Senovilla, Laura ^a,b,c   Eggermont, Alexander ^b   Fridman, Wolf Hervé ^d,e,f,g   Galon, Jérôme ^d,e,f,g,h   Zitvogel, Laurence ^b,e   Kroemer, Guido ^a,d,f,g   Galluzzi, Lorenzo ^a,d,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut Gustave Roussy   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e INSERM   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h SORBONNE UNIVERSITÉ   (France)

Author keywords

ATP; Autophagy; Calreticulin; Dendritic cells; Epothilone B; HMGB1

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPOTHILONE B; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMIQUIMOD; INTERLEUKIN 12; IPILIMUMAB; IRINOTECAN; METHOTREXATE; MITOXANTRONE; OXALIPLATIN; SORAFENIB; TEMSIROLIMUS; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR AGONIST; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VINBLASTINE;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; B CELL LYMPHOMA; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMATOUS PERITONITIS; CHEMOEMBOLIZATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; COLORECTAL CARCINOMA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS TUMOR; GASTROESOPHAGEAL TUMOR; GASTROINTESTINAL TUMOR; GENITAL TRACT CANCER; GERM CELL TUMOR; HEAD AND NECK CANCER; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKEMIA; LIVER CELL CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; LUNG CARCINOMA; LUNG SMALL CELL CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MELANOMA; MESOTHELIOMA; METASTASIS; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NEPHROBLASTOMA; NEPHROTIC SYNDROME; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECTUM CARCINOMA; RECURRENT CANCER; RETINOBLASTOMA; REVIEW; SARCOMA; SOFT TISSUE CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CARCINOMA; STOMACH TUMOR; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT TUMOR; UTERINE CERVIX CARCINOMA; UTERINE TUBE CARCINOMA; UTERUS CARCINOMA;

EID: 84885692390     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23510     Document Type: Review

References (97)

1. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19:107-20; PMID:21760595; http://dx.doi.org/10.1038/cdd.2011.96.
2. Galluzzi L, Maiuri MC, Vitale I, Zischka H, Castedo M, Zitvogel L, et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 2007; 14:1237-43; PMID:17431418; http://dx.doi.org/10.1038/sj.cdd.4402148.
3. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2012; In press; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008.
4. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140:798-804; PMID:20303871; http://dx.doi.org/10.1016/j.cell.2010.02.015.
5. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523.
6. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1.
7. Melcher A, Todryk S, Hardwick N, Ford M, Jacobson M, Vile RG. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. Nat Med 1998; 4:581-7; PMID:9585232; http://dx.doi.org/10.1038/nm0598-581.
8. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2:185-94; PMID:11913069; http://dx.doi.org/10.1038/nri749.
9. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8:3723-8; PMID:19855167; http://dx.doi.org/10.4161/cc.8.22.10026.
10. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science.1208347.
11. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622.
12. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31:1062-79; PMID:22252128; http://dx.doi.org/10.1038/emboj.2011.497.
13. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000; 191:1957-64; PMID:10839810; http://dx.doi.org/10.1084/jem.191.11.1957.
14. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol 2012; 13:343-51; PMID:22430787; http://dx.doi.org/10.1038/ni.2224.
15. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028.
16. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380.
17. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114:589-95; PMID:19349616; http://dx.doi.org/10.1182/blood-2009-02-206870.
18. Korbelik M, Zhang W, Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother 2011; 60:1431-7; PMID:21644033; http://dx.doi.org/10.1007/s00262-011-1047-x.
19. Sanovic R, Verwanger T, Hartl A, Krammer B. Low dose hypericin-PDT induces complete tumor regression in BALB/c mice bearing CT26 colon carcinoma. Photodiagnosis Photodyn Ther 2011; 8:291-6; PMID:22122915; http://dx.doi.org/10.1016/j.pdpdt.2011.04.003.
20. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:43ra99; PMID:22814852; http://dx.doi.org/10.1126/scitranslmed.3003807.
21. Kepp O, Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, et al. Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects. Oncoimmunology 2012; 1:1640-2; PMID:23264921; http://dx.doi.org/10.4161/onci.21684.
22. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788.
23. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915.
24. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950.
25. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29:482-91; PMID:19881547; http://dx.doi.org/10.1038/onc.2009.356.
26. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science.1224922.
27. Garrido G, Rabasa A, Sánchez B, López MV, Blanco R, López A, et al. Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody. J Immunol 2011; 187:4954-66; PMID:21984704; http://dx.doi.org/10.4049/jimmunol.1003477.
28. Sonnemann J, Gressmann S, Becker S, Wittig S, Schmudde M, Beck JF. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro. Cancer Chemother Pharmacol 2010; 66:611-6; PMID:20221600; http://dx.doi.org/10.1007/s00280-010-1302-4.
29. Molinari R, D'Eliseo D, Manzi L, Zolla L, Velotti F, Merendino N. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure. Cancer Immunol Immunother 2011; 60:1503-7; PMID:21779875; http://dx.doi.org/10.1007/s00262-011-1074-7.
30. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007; 109:4839-45; PMID:17299090; http://dx.doi.org/10.1182/blood-2006-10-054221.
31. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res 2012; 72:2609-21; PMID:22461509; http://dx.doi.org/10.1158/0008-5472.CAN-11-3185.
32. Chen HM, Wang PH, Chen SS, Wen CC, Chen YH, Yang WC, et al. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cellbased cancer vaccine. Cancer Immunol Immunother 2012; 61:1989-2002; PMID:22527248; http://dx.doi.org/10.1007/s00262-012-1258-9.
33. Chen J, Xie J, Jiang Z, Wang B, Wang Y, Hu X. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 2011; 30:4297-306; PMID:21516121; http://dx.doi.org/10.1038/onc.2011.137.
34. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011; 30:1147-58; PMID:21151176; http://dx.doi.org/10.1038/onc.2010.500.
35. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494.
36. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696.
37. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549.
38. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938.
39. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial Watch: Cardiac glycosides and cancer therapy. OncoImmunology 2013; 2; In press.
40. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009.
41. Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, et al. Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology 2013; 2; In press; http://dx.doi.org/10.4161/onci.22789.
42. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDAapproved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931.
43. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi.org/10.4161/onci.20459.
44. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026.
45. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428.
46. Garrido G, Sanchez B, Rodriguez HM, Lorenzano P, Alonso D, Fernandez LE. 7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies. Hybrid Hybridomics 2004; 23:168-75; PMID:15312307; http://dx.doi.org/10.1089/1536859041224280.
47. de La Motte Rouge T, Galluzzi L, Olaussen KA, Zermati Y, Tasdemir E, Robert T, et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res 2007; 67:6253-62; PMID:17616683; http://dx.doi.org/10.1158/0008-5472.CAN-07-0538.
48. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http://dx.doi.org/10.1182/blood-2007-07-100362.
49. Goldberg RM. Cetuximab. Nat Rev Drug Discov 2005; (Suppl): S10-1; PMID:15962524; http://dx.doi.org/10.1038/nrd1728.
50. Pollack BP. EGFR inhibitors, MHC expression and immune responses: Can EGFR inhibitors be used as immune response modifiers? Oncoimmunology 2012; 1:71-4; PMID:22720215; http://dx.doi.org/10.4161/onci.1.1.18073.
51. Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012; 18:1726-34; PMID:22307137; http://dx.doi.org/10.1158/1078-0432.CCR-11-2821.
52. Navid F, Baker SD, McCarville MB, Stewart CF, Billups CA, Wu J, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res 2013; 19:236-46; PMID:23143218; http://dx.doi.org/10.1158/1078-0432.CCR-12-1897.
53. Ellis LM. Bevacizumab. Nat Rev Drug Discov 2005; (Suppl): S8-9; PMID:15962523; http://dx.doi.org/10.1038/nrd1727.
54. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-44; PMID:17016424; http://dx.doi.org/10.1038/nrd2130.
55. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; In press; PMID:22842478; http://dx.doi.org/10.1038/nm.2883.
56. Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 2012; 18:2638-47; PMID:22374332; http://dx.doi.org/10.1158/1078-0432.CCR-11-3203.
57. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al.; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-81; PMID:17538086; http://dx.doi.org/10.1056/NEJMoa066838.
58. Moroney J, Fu S, Moulder S, Falchook G, Helgason T, Levenback C, et al. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/ hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res 2012; 18:5796-805; PMID:22927482; http://dx.doi.org/10.1158/1078-0432.CCR-12-1158.
59. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol 2012; 13:1234-41; PMID:23153506; http://dx.doi.org/10.1016/S1470-2045(12)70476-X.
60. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al.; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366:2189-97; PMID:22551107; http://dx.doi.org/10.1056/NEJMoa1200966.
61. Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? Lancet Oncol 2011; 12:8-9; PMID:21050812; http://dx.doi.org/10.1016/S1470-2045(10)70237-0.
62. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817-25; PMID:21561347; http://dx.doi.org/10.1056/NEJMoa1011923.
63. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial. J Clin Oncol 2013; 31:23-9; PMID:23213101; http://dx.doi.org/10.1200/JCO.2012.44.4869.
64. Mondo EL, Noel MS, Katz AW, Schoeniger LO, Hezel AF. Unresectable locally advanced pancreatic cancer: Treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. J Clin Oncol 2013; 31:e37-9; PMID:23233707; http://dx.doi.org/10.1200/JCO.2012.44.0339.
65. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al.; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379:315-21; PMID:22226517; http://dx.doi.org/10.1016/S0140-6736(11)61873-4.
66. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012; 13:181-8; PMID:22192731; http://dx.doi.org/10.1016/S1470-2045(11)70301-1.
67. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30:3841-7; PMID:22987083; http://dx.doi.org/10.1200/JCO.2011.38.8082.
68. Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ. Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo. Clin Cancer Res 2012; 18:161-9; PMID:22065081; http://dx.doi.org/10.1158/1078-0432.CCR-11-1413.
69. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012; 18:1639-42; PMID:23104132; http://dx.doi.org/10.1038/nm.2919.
70. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov 2011; 10:411-2; PMID:21629286; http://dx.doi.org/10.1038/nrd3463.
71. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012; 1:997-9; PMID:23189245; http://dx.doi.org/10.4161/onci.19865.
72. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34; PMID:16915295; http://dx.doi.org/10.1038/nrc1974.
73. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2012; 31:71-5; PMID:23242161; http://dx.doi.org/10.1038/nbt.2459.
74. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53; PMID:17945478; http://dx.doi.org/10.1016/j.ejca.2007.08.028.
75. Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor F, Meyer A, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. PLoS One 2012; 7:e33214; PMID:22485139; http://dx.doi.org/10.1371/journal.pone.0033214.
76. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384.
77. Tajeddine N, Galluzzi L, Kepp O, Hangen E, Morselli E, Senovilla L, et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008; 27:4221-32; PMID:18362892; http://dx.doi.org/10.1038/onc.2008.63.
78. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res 2012; 18:510-23; PMID:22128301; http://dx.doi.org/10.1158/1078-0432.CCR-11-1973.
79. Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly(ADPRibose) polymerase in vitro. Clin Cancer Res 2012; 18:1655-62; PMID:22291137; http://dx.doi.org/10.1158/1078-0432.CCR-11-2890.
80. Friedberg JW. Rituximab for early-stage diffuse large-B-cell lymphoma. Lancet Oncol 2006; 7:357-9; PMID:16648037; http://dx.doi.org/10.1016/S1470-2045(06)70668-4.
81. Gajraj E, Chung H, Longson C, Stevens A. Rituximab for follicular non-Hodgkin lymphoma. Lancet Oncol 2008; 9:320-1; PMID:18405852; http://dx.doi.org/10.1016/S1470-2045(08)70036-6.
82. Mayor S. MET inhibitors: translating from bench to bedside. Lancet Oncol 2011; 12:14; PMID:21249721; http://dx.doi.org/10.1016/S1470-2045(10)70302-8.
83. Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296-303; PMID:19383969; http://dx.doi.org/10.1182/blood-2008-09-038935.
84. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
85. Malvicini M, Alaniz L, Bayo J, Garcia M, Piccioni F, Fiore E, et al. Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology 2012; 1:1038-47; PMID:23170252; http://dx.doi.org/10.4161/onci.20684.
86. Shultz LD, Brehm MA, Garcia-Martinez JV, Greiner DL. Humanized mice for immune system investigation: progress, promise and challenges. Nat Rev Immunol 2012; 12:786-98; PMID:23059428; http://dx.doi.org/10.1038/nri3311.
87. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-33; PMID:7757983.
88. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997; 272:2534-41; PMID:8999970; http://dx.doi.org/10.1074/jbc.272.4.2534.
89. Nicolaou KC, Winssinger N, Pastor J, Ninkovic S, Sarabia F, He Y, et al. Synthesis of epothilones A and B in solid and solution phase. Nature 1997; 387:268-72; PMID:9153390; http://dx.doi.org/10.1038/387268a0.
90. Cowden CJ, Paterson I. Synthetic chemistry. Cancer drugs better than taxol? Nature 1997; 387:238-9; PMID:9153384; http://dx.doi.org/10.1038/387238a0.
91. Service RF. Tumor-killer made; how does it work? Science 1996; 274:2009; PMID:8984658; http://dx.doi.org/10.1126/science.274.5295.2009.
92. Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19:977-83; PMID:18296423; http://dx.doi.org/10.1093/annonc/mdm591.
93. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23:1439-46; PMID:15735119; http://dx.doi.org/10.1200/JCO.2005.09.042.
94. Rustin G, Reed N, Jayson GC, Ledermann JA, Adams M, Perren T, et al. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Ann Oncol 2011; 22:2411-6; PMID:21372124; http://dx.doi.org/10.1093/annonc/mdq780.
95. Vansteenkiste J, Lara PN Jr., Le Chevalier T, Breton JL, Bonomi P, Sandler AB, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol 2007; 25:3448-55; PMID:17606973; http://dx.doi.org/10.1200/JCO.2006.09.7097.
96. Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011; 20:107-17; PMID:21142807; http://dx.doi.org/10.1517/13543784.2011.542148.
97. Kaklamani VG, Xu BH, Gomez HL. Global experience with ixabepilone in breast cancer. Expert Rev Anticancer Ther 2011; 11:683-92; PMID:21554041; http://dx.doi.org/10.1586/era.11.41.